Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
GLP-1 weight-loss drugs show unexpected psychiatric benefits in largest study to date

GLP-1 weight-loss drugs show unexpected psychiatric benefits in largest study to date

New Capabilities

A Swedish study of nearly 100,000 people finds semaglutide users experienced 42% fewer psychiatric hospitalizations, raising the prospect of a new class of mental health treatment

March 22nd, 2026: Largest study finds semaglutide cuts psychiatric crises by 42%

Overview

Drugs originally designed to control blood sugar and reduce weight may also protect the brain. A study of 95,490 people in Sweden, published in The Lancet Psychiatry on March 22, 2026, found that semaglutide (the compound in Ozempic and Wegovy) reduced psychiatric hospitalizations, worsening depression, and substance-use crises.

Compared to periods without the drug, semaglutide users experienced 42% fewer psychiatric hospitalizations, 44% less worsening depression, and 47% fewer substance-use-related crises.

In January 2026, the United States Food and Drug Administration (FDA) removed suicide-risk warnings from GLP-1 drug labels after concluding the medications posed no psychiatric danger. Now researchers are asking a bolder question: could these drugs, already prescribed to tens of millions worldwide for diabetes and obesity, be an entirely new avenue for treating mental illness? The answer hinges on whether randomized clinical trials (designed to prove causation, not just correlation) can confirm what the observational data suggests.

Why it matters

If confirmed, drugs already taken by tens of millions could become a new treatment class for depression, anxiety, and addiction.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

42%
Reduction in psychiatric decompensation
Composite measure including psychiatric hospitalization, extended sick leave, self-harm hospitalization, and death by suicide during semaglutide use versus non-use periods
95,490
Study participants
People with pre-existing depression or anxiety who used antidiabetic medications in Sweden between 2009 and 2022
47%
Reduction in substance use disorder crises
Lower rate of hospitalizations and extended sick leave related to substance use disorders during GLP-1 treatment
$62B+
Global GLP-1 market size
Estimated annual revenue for GLP-1 receptor agonist drugs in 2025, projected to exceed $130 billion by 2035

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Heidi Taipale
Heidi Taipale
Active researcher
 Jari Tiihonen
Jari Tiihonen
Active researcher

Organizations Involved

Novo Nordisk
Novo Nordisk
Pharmaceutical company
Manufacturer of semaglutide (Ozempic, Wegovy)

Danish pharmaceutical company that manufactures semaglutide, the GLP-1 drug showing the strongest psychiatric benefit signal in the new study.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Removed psychiatric risk warnings from GLP-1 labels in January 2026

The FDA reversed course on GLP-1 psychiatric warnings in January 2026, requesting removal of suicidal behavior labels based on a meta-analysis of 91 trials and a study of over 2.2 million users.
Karolinska Institutet
Karolinska Institutet
Research university
Co-produced the March 2026 study

One of Europe's leading medical universities, based in Stockholm, and a co-institutional home for the research group behind the Lancet Psychiatry study.

Timeline

October 2008 March 2026

10 events Latest: March 22nd, 2026 · 4 months ago
Tap a bar to jump to that date

  1. Largest study finds semaglutide cuts psychiatric crises by 42%

    Latest Research

    A study of 95,490 people published in The Lancet Psychiatry found semaglutide reduced psychiatric decompensation by 42%, with 44% less worsening depression, 38% less worsening anxiety, and 47% fewer substance-use-disorder crises. The within-individual design compared each person's outcomes during treatment versus non-treatment periods.

  2. FDA removes suicide-risk warnings from GLP-1 drug labels

    Regulatory

    Based on a meta-analysis of 91 trials and a retrospective study of 2.2 million users, the FDA requested drug manufacturers remove suicidal behavior and ideation warnings from GLP-1 receptor agonist labels—a significant reversal from the caution that followed rimonabant's withdrawal.

  3. Meta-analysis of 80 trials finds no psychiatric harm from GLP-1 drugs

    Research

    A JAMA Psychiatry meta-analysis of 80 double-blind, placebo-controlled trials with 107,860 adults concluded GLP-1 receptor agonists did not increase psychiatric side effects compared to placebo, with small improvements in well-being. A critical limitation: people with psychiatric histories were generally excluded.

  4. Semaglutide reduces heavy drinking in randomized trial

    Research

    A randomized controlled trial published in JAMA Psychiatry found low-dose semaglutide significantly reduced weekly alcohol cravings and heavy drinking days in 48 patients with alcohol use disorder over nine weeks.

  5. Major veterans study links GLP-1 drugs to reduced addiction risk

    Research

    Washington University researchers analyzing over 600,000 veterans found GLP-1 medications associated with 18–25% reduced risk of developing substance use disorders across all major addictive substances, with 50% fewer drug-related deaths at three years among those with pre-existing disorders.

  6. Pharmacovigilance studies yield conflicting psychiatric signals

    Research

    Multiple studies using the FDA's adverse event reporting system produced contradictory results—some found elevated psychiatric event reports with semaglutide, while others found no pattern.

  7. First systematic reviews examine GLP-1 antidepressant effects

    Research

    A systematic review and meta-analysis in The American Journal of Geriatric Psychiatry examined early evidence for antidepressant effects of GLP-1 receptor agonists, finding preliminary signals.

  8. FDA approves Wegovy for weight management

    Regulatory

    Semaglutide received FDA approval at higher doses for chronic weight management, triggering an explosion in off-label and on-label prescriptions worldwide.

  9. FDA approves Ozempic for type 2 diabetes

    Regulatory

    Novo Nordisk's semaglutide received FDA approval for diabetes under the brand name Ozempic, beginning its path to becoming one of the best-selling drugs in history.

  10. Rimonabant withdrawn over psychiatric side effects

    Regulatory

    The European Medicines Agency suspended the anti-obesity drug rimonabant after reports of severe depression and suicidality. The withdrawal created lasting caution about obesity drugs and mental health, leading regulators to require psychiatric warnings on subsequent weight-loss medications.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1991–1998

Sildenafil repurposing: from failed heart drug to Viagra (1991–1998)

Pfizer developed sildenafil as a treatment for angina and hypertension. Clinical trials in Wales showed disappointing cardiovascular results, but male participants reported an unexpected side effect: sustained erections. Pfizer pivoted the drug's development entirely, and the FDA approved Viagra for erectile dysfunction in March 1998.

Then

Viagra generated $1 billion in sales in its first year, becoming one of the fastest-adopted drugs in history.

Now

Sildenafil was later approved a third time—as Revatio for pulmonary arterial hypertension—making it one of the most successfully repurposed compounds in pharmaceutical history.

Why this matters now

The Viagra story demonstrates how a drug's most important medical application can emerge from unexpected clinical observations. GLP-1 drugs, developed for metabolic conditions, may be following a similar trajectory if psychiatric benefits are confirmed.

1949–1970

Lithium's psychiatric discovery (1949–1970)

Australian psychiatrist John Cade discovered lithium's calming properties accidentally in 1949 while injecting lithium-urine solutions into guinea pigs as part of unrelated research. He published clinical results showing lithium improved mania, but adoption was slow—partly because lithium is a natural element that no company could patent. Danish psychiatrist Mogens Schou championed lithium through rigorous trials over two decades.

Then

The FDA did not approve lithium for bipolar disorder until 1970, more than twenty years after Cade's discovery.

Now

Lithium remains the only medication proven to prevent suicide in mood disorders and is still considered the gold standard for bipolar maintenance therapy, despite being one of the oldest and cheapest psychiatric drugs available.

Why this matters now

Lithium illustrates both the promise and the friction of psychiatric drug discovery through serendipity. GLP-1 drugs face a faster path—they are already widely prescribed, well-characterized, and backed by large pharmaceutical companies—but the same fundamental question applies: can observational signals survive the rigor of controlled trials?

June 2006–October 2008

Rimonabant withdrawal: the anti-obesity drug that worsened mental health (2006–2008)

Sanofi-Aventis launched rimonabant, an endocannabinoid receptor blocker, as an anti-obesity treatment in Europe in 2006. Post-marketing surveillance revealed a pattern of severe depression, anxiety, and suicidality. The European Medicines Agency suspended rimonabant in October 2008, and the FDA never approved it in the United States.

Then

Rimonabant was pulled from all markets. Sanofi-Aventis wrote off its investment in the drug.

Now

The episode created lasting regulatory caution about the psychiatric effects of weight-loss drugs. Subsequent obesity medications, including GLP-1 drugs, were required to carry psychiatric warnings—the same warnings the FDA removed from GLP-1 labels in January 2026.

Why this matters now

Rimonabant's failure is the direct reason GLP-1 drugs carried psychiatric warnings in the first place. The new study represents a complete inversion of the rimonabant story: rather than weight-loss drugs causing psychiatric harm, they may provide psychiatric protection. This reversal makes the evidence bar for a psychiatric indication both higher and more consequential.

Sources

(8)
+2
The Lancet Psychiatry ScienceDaily Global News Karolinska Institutet Medscape U.S. Food and Drug Administration JAMA Psychiatry Science Media Centre